Literature DB >> 7844372

Biliary complications in the treatment of unsubstantiated Lyme disease.

P J Ettestad1, G L Campbell, S F Welbel, C A Genese, K C Spitalny, C M Marchetti, D T Dennis.   

Abstract

Treatment of unsubstantiated Lyme disease has led to serious complications in some cases. Two case-control studies, based on information in clinical records of patients discharged with a diagnosis of Lyme disease during 1990-1992, were conducted at a central New Jersey hospital. Twenty-five patients with biliary disease were identified, and 52 controls were selected from 1352 patients with suspected Lyme disease. Only 3% of 71 evaluatable subjects met the study criteria for disseminated Lyme disease. Patients with biliary disease were more likely than were antibiotic controls to have received ceftriaxone and more likely than ceftriaxone controls to have received a daily ceftriaxone dose > or = 40 mg/kg and to be < or = 18 years old. Fourteen of 25 biliary case-patients underwent cholecystectomy; all had histopathologic evidence of cholecystitis and 12 had gallstones. Thus, treatment of unsubstantiated diagnoses of Lyme disease is associated with biliary complications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7844372     DOI: 10.1093/infdis/171.2.356

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

Review 1.  The emergence of Lyme disease.

Authors:  Allen C Steere; Jenifer Coburn; Lisa Glickstein
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  Evaluation of the C6 Lyme Enzyme Immunoassay for the Diagnosis of Lyme Disease in Children and Adolescents.

Authors:  Susan C Lipsett; John A Branda; Alexander J McAdam; Louis Vernacchio; Caroline D Gordon; Catherine R Gordon; Lise E Nigrovic
Journal:  Clin Infect Dis       Date:  2016-06-28       Impact factor: 9.079

3.  A symptomatic child with ceftriaxone-associated biliary pseudolithiasis.

Authors:  Naoki Kutuya; Yutaka Ozaki; Tadaharu Okazaki
Journal:  J Med Ultrason (2001)       Date:  2008-09-19       Impact factor: 1.314

Review 4.  Lyme disease.

Authors:  Thomas S Murray; Eugene D Shapiro
Journal:  Clin Lab Med       Date:  2010-03       Impact factor: 1.935

Review 5.  Persistent Symptoms After Treatment of Lyme Disease.

Authors:  Adriana Marques
Journal:  Infect Dis Clin North Am       Date:  2022-09       Impact factor: 5.905

6.  Appropriateness of Lyme disease serologic testing.

Authors:  Alan H Ramsey; Edward A Belongia; Po-Huang Chyou; Jeffrey P Davis
Journal:  Ann Fam Med       Date:  2004 Jul-Aug       Impact factor: 5.166

7.  BBK07, a dominant in vivo antigen of Borrelia burgdorferi, is a potential marker for serodiagnosis of Lyme disease.

Authors:  Adam S Coleman; Utpal Pal
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

Review 8.  Diagnosis, treatment, and prevention of Lyme disease in children.

Authors:  Stephen C Eppes
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Lyme disease testing by large commercial laboratories in the United States.

Authors:  Alison F Hinckley; Neeta P Connally; James I Meek; Barbara J Johnson; Melissa M Kemperman; Katherine A Feldman; Jennifer L White; Paul S Mead
Journal:  Clin Infect Dis       Date:  2014-05-30       Impact factor: 9.079

10.  Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease.

Authors:  Raphael B Stricker; Allison K Delong; Christine L Green; Virginia R Savely; Stanley N Chamallas; Lorraine Johnson
Journal:  Int J Gen Med       Date:  2011-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.